Immuneering Corporation
IMRX
$1.47
-$0.07-4.55%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12M | 4.38M | 3.87M | 4.05M | 4.46M |
| Depreciation & Amortization | 7.30K | 7.30K | 7.30K | 7.30K | 7.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.33M | 16.30M | 13.93M | 13.51M | 14.68M |
| Operating Income | -15.33M | -16.30M | -13.93M | -13.51M | -14.68M |
| Income Before Tax | -14.31M | -15.08M | -12.60M | -12.19M | -13.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.31M | -15.08M | -12.60M | -12.19M | -13.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.31M | -15.08M | -12.60M | -12.19M | -13.60M |
| EBIT | -15.33M | -16.30M | -13.93M | -13.51M | -14.68M |
| EBITDA | -15.23M | -16.20M | -13.84M | -13.42M | -14.60M |
| EPS Basic | -0.49 | -0.52 | -0.43 | -0.43 | -0.51 |
| Normalized Basic EPS | -0.31 | -0.34 | -0.27 | -0.27 | -0.33 |
| EPS Diluted | -0.49 | -0.52 | -0.43 | -0.43 | -0.51 |
| Normalized Diluted EPS | -0.31 | -0.34 | -0.27 | -0.27 | -0.33 |
| Average Basic Shares Outstanding | 29.37M | 29.27M | 29.27M | 28.65M | 26.44M |
| Average Diluted Shares Outstanding | 29.37M | 29.27M | 29.27M | 28.65M | 26.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
